Table 1 The characteristics of included studies
Authors | Countries Years | Type of study | Total sample size | Sample size (intervention) | Sample size (comparison | No. of death in intervention group | No. of death in placebo group | Comparison | Age | BMI |
|---|---|---|---|---|---|---|---|---|---|---|
V. C. Veiga, et al22 | Brazil 2021 | RCT | 129 | 65 | 64 | 30 | 9 | Placebo | 57.5 | Â |
I. O. Rosas, et al23 | UK 2021 | RCT | 438 | 294 | 144 | 57 | 27 | Placebo | 60.8 | Â |
D. Wang, et al24 | USA 2020 | RCT | 65 | 34 | 31 | 2 | 4 | Placebo | 63 | Â |
R. Capra, et al25 | Italy 2020 | RCT | 85 | 62 | 23 | 2 | 11 | Placebo | 65 | Â |
A. Rashad, et al26 | Egypt 2021 | RCT | 149 | 74 | 75 | 60 | 45 | Dexamethasone | 62.3 | Â |
O. Hermine, et al27 | France 2021 | RCT | 130 | 63 | 67 | 7 | 8 | Placebo | 63.7 | 27.7 |
A. S. Soin, et al28 | India 2021 | RCT | 180 | 91 | 89 | 11 | 15 | Placebo | 55 | 26.9 |
Perrone, F., et al29 | Italy 2020 | RCT | 1221 | 301 | 920 | 8 | 11 | Placebo | Â | Â |
J. H. Stone, et al30 | UK 2020 | RCT | 242 | 161 | 81 | 9 | 3 | Placebo | 59.8 | 30.1 |
D. M. Hamed, et al31 | United Arab Emirates 2021 | RCT | 76 | 49 | 27 | 3 | 5 | Difference in dosage | 48 | Â |
Hong Zhao, et al32 | China 2021 | RCT | 26 | 14 | 7 | 0 | 2 | Favipiravir | 75 | 24.8 |
G. W. Strohbehn, et al33 | UK 2021 | CT | 32 | 12 | 20 | 2 | 3 | Difference in dosage | 69 | Â |
E. H. Baker, et al34 | UK 2021 | RCT | 17 | 11 | 6 | 2 | 0 | Placebo | Â | Â |
A. C. Gordon, et al35 | UK 2021 | RCT | 755 | 353 | 402 | 99 | 142 | Placebo | 61.4 | Â |
A. C. Gordon, et al35 | UK 2021 | RCT | 450 | 48 | 402 | 10 | 142 | Sarilumab | 61.4 | Â |
F. Dastan, et al36 | Iran 2020 | CT | 42 | 20 | 22 | 1 | 6 | Placebo | 56 | Â |
G. Pomponio, et al37 | Italy 2020 | RCT | 46 | 25 | 21 | 7 | 0 | Placebo | 66.5 | Â |
C. Salama, et al38 | United States, Mexico, Kenya, South Africa, Peru, or Brazil 2021 | RCT | 388 | 259 | 129 | 26 | 11 | Placebo | 55.9 | 32.4 |